Table 3.
Key parameters input in the model.
| Variable | Value | Range | Distribution | References |
|---|---|---|---|---|
| Utilities | ||||
| Stable state | 0.68 | 0.54 to 0.82 | Beta | 20,21 |
| Progressive state | 0.42 | 0.34 to 0.50 | Beta | 20,21 |
| Disutility due to AEs (grade ≥ 3) | 0.20 | 0.16 to 0.24 | Beta | 22 |
| Costs per cycle, $ | ||||
| Eribulin | 615.48 | 492.38 to 738.58 | Gamma | Local charge |
| Dacarbazine | 164.63 | 131.70 to 197.56 | Gamma | Local charge |
| Tests | 193.96 | 155.17 to 232.75 | Gamma | Local charge |
| Outpatient fees | 6.36 | 5.09 to 7.63 | Gamma | Local charge |
| Grade ≥ 3AEs in eribulin group | 38.98 | 31.18 to 46.78 | Gamma | Local charge |
| Grade ≥ 3AEs in dacarbazine group | 152.71 | 122.17 to 183.25 | Gamma | Local charge |
| Costs for progressive state | 503.93 | 403.14 to 604.72 | Gamma | Local charge |